12 Communication Services Stocks Moving In Thursday’s Intraday Session
Gainers Asset Entities (NASDAQ:ASST) shares rose 24.6% to $0.57 during Thursday’s regular session. The company’s market cap stands…
The Latest Analyst Ratings for IHS Holding
IHS Holding (NYSE:IHS) has observed the following analyst ratings within the last quarter: Bullish Somewhat Bullish Indifferent Somewhat…
Earnings Scheduled For November 14, 2023
Companies Reporting Before The Bell
• CureVac (NASDAQ:CVAC) is likely to report quarterly loss at $0.24 per share on revenue of $18.00 million.
Recap: IHS Holding Q3 Earnings
IHS Holding (NYSE:IHS) reported its Q3 earnings results on Tuesday, November 14, 2023 at 06:12 AM. Here’s what…
11 Communication Services Stocks Moving In Tuesday’s After-Market Session
Gainers Grom Social Enterprises (NASDAQ:GROM) stock rose 12.2% to $1.74 during Tuesday’s after-market session. This security traded at…
DraftKings To Rally Around 35%? Here Are 10 Other Analyst Forecasts For Tuesday
Berenberg cut the price target for American Airlines Group Inc. (NASDAQ: AAL) from $26 to $23. Berenberg analyst Adrian Yanoshik maintained an Outperform rating. American Airlines shares fell 0.4% to $12.86 in pre-market trading.
Steelcase, Western Digital, Bausch Health And Other Big Stocks Moving Higher On Wednesday
U.S. stocks traded mostly higher on Wednesday. Here are some big stocks recording gains in today’s session.
Steelcase Inc. (NYSE: SCS) shares surged 27.3% to $11.22. Steelcase reported better-than-expected results for its second quarter.
Stocks That Hit 52-Week Lows On Tuesday
During Tuesday's session, 275 companies made new 52-week lows.
Top 5 Tech And Telecom Stocks You’ll Regret Missing This Month
The most oversold stocks in the communication services sector presents an opportunity to buy into undervalued companies.
Why Avantax Are Trading Higher By Over 27%? Here Are Other Stocks Moving In Monday’s Mid-Day Session
Gainers
Crinetics Pharmaceuticals, Inc. (NASDAQ: CRNX) jumped 76% to $28.13 after the company's once-daily oral paltusotine achieved the primary and secondary endpoints in the Phase 3 PATHFNDR-1 study in acromegaly.